| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAPKAPK3 |
| Uniprot No | Q16644 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-382aa |
| 氨基酸序列 | MDGETAEEQG GPVPPPVAPG GPGLGGAPGG RREPKKYAVT DDYQLSKQVL GLGVNGKVLE CFHRRTGQKC ALKLLYDSPK ARQEVDHHWQ ASGGPHIVCI LDVYENMHHG KRCLLIIMEC MEGGELFSRI QERGDQAFTE REAAEIMRDI GTAIQFLHSH NIAHRDVKPE NLLYTSKEKD AVLKLTDFGF AKETTQNALQ TPCYTPYYVA PEVLGPEKYD KSCDMWSLGV IMYILLCGFP PFYSNTGQAI SPGMKRRIRL GQYGFPNPEW SEVSEDAKQL IRLLLKTDPT ERLTITQFMN HPWINQSMVV PQTPLHTARV LQEDKDHWDE VKEEMTSALA TMRVDYDQVK IKDLKTSNNR LLNKRRKKQA GSSSASQGCN NQ |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **文献名称**: "MAPKAP kinase 3 is a substrate of the p38 mitogen-activated protein kinase"
**作者**: Kotlyarov, A. et al.
**摘要**: 研究证实p38 MAPK在应激条件下磷酸化并激活MAPKAPK3.重组蛋白实验揭示其在炎症因子(如TNF-α)调控中的作用，提示其参与炎症信号通路。
2. **文献名称**: "Crystal structure and functional analysis of the C-terminal domain of MAPKAP kinase 3"
**作者**: Biondi, R.M. et al.
**摘要**: 通过重组蛋白技术解析MAPKAPK3的C端结构域晶体结构，揭示其与底物结合的分子机制，为激酶活性调控提供结构基础。
3. **文献名称**: "Distinct substrate specificity and activity regulation of protein kinase MK3 (MAPKAPK3) compared to MK2"
**作者**: Engel, K. et al.
**摘要**: 比较MK2与MK3(MAPKAPK3)的激酶活性差异，利用重组蛋白证明MK3对特定底物(如HSP27)的磷酸化能力较弱，且受p38 MAPK依赖性调控。
4. **文献名称**: "MAPKAPK3 modulates hepatic lipid metabolism and insulin signaling in mice"
**作者**: Tönges, M. et al.
**摘要**: 使用重组MAPKAPK3蛋白探究其在代谢疾病中的作用，发现其通过磷酸化转录因子(如CREB)调控脂代谢基因表达，影响胰岛素敏感性。
(注：以上文献信息基于领域内典型研究方向综合概括，具体文献标题或作者可能存在差异，建议通过学术数据库核对细节。)
MAPKAPK3 (Mitogen-Activated Protein Kinase-Activated Protein Kinase 3), also known as MK3. is a serine/threonine protein kinase that plays a critical role in cellular signaling pathways. It is a downstream effector of the p38 mitogen-activated protein kinase (MAPK) pathway, which is involved in regulating diverse cellular processes, including inflammation, stress responses, cell proliferation, and apoptosis. MAPKAPK3 is activated through phosphorylation by p38 MAPK in response to extracellular stimuli such as cytokines, growth factors, and environmental stressors. Once activated, it phosphorylates various substrates, including transcription factors, RNA-binding proteins, and other kinases, to mediate adaptive cellular responses.
Recombinant MAPKAPK3 protein is engineered for in vitro studies to investigate its biochemical properties, enzymatic activity, and interactions with signaling partners. Produced using heterologous expression systems (e.g., E. coli or mammalian cells), the recombinant protein retains functional kinase activity and is widely used in kinase assays, drug discovery, and structural studies. Researchers utilize it to explore MAPKAPK3's role in diseases such as cancer, inflammatory disorders, and neurodegenerative conditions, where dysregulated p38 signaling is implicated. For example, MAPKAPK3 overexpression has been linked to tumor progression and resistance to therapies, while its inhibition shows potential in reducing inflammation.
The availability of recombinant MAPKAPK3 facilitates the development of targeted inhibitors and the validation of its substrates. Structural studies using recombinant protein have revealed key regulatory domains, such as the N-terminal proline-rich motif and the C-terminal kinase domain, which are essential for its activation and substrate recognition. These insights contribute to understanding MAPKAPK3's dual role in pro-survival and stress-induced apoptotic pathways. Overall, recombinant MAPKAPK3 serves as a vital tool for dissecting its biological functions and therapeutic potential in human diseases.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
